DS-1040b + Aspirin
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Trial Timeline
Jan 1, 2014 → Feb 1, 2014
NCT ID
NCT02071004About DS-1040b + Aspirin
DS-1040b + Aspirin is a phase 1 stage product being developed by Daiichi Sankyo for Acute Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT02071004. Target conditions include Acute Ischemic Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02071004 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Ischemic Stroke